Biotech drug developer Introgen Therapeutics Inc. on Tuesday said the European Patent Office issued a patent covering the company's platform for killing cancer cells.
The patent, which is one of a family of patents issued to University of Texas and licensed to Introgen exclusively, covers one or more of 40 tumor suppressor genes for inducing programmed cell death in cancer cells.
The company seeks to use synthetic nanoparticles to deliver the genes to cancer cells, and shows promise in treating lung cancers that have spread.
Introgen shares rose a penny to $4.74 in afternoon trading on the Nasdaq.
source - BusinessWeek